$VIRX
Viracta Therapeutics, Inc.

2015 Q3 Form 10-Q Financial Statement

#000156459015009661 Filed on November 05, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2014 Q3
Revenue $683.0K $854.0K
YoY Change -20.02% -57.06%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.990M $7.230M
YoY Change -44.81% 157.3%
% of Gross Profit
Research & Development $5.259M $6.939M
YoY Change -24.21% -0.26%
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K
YoY Change -100.0% 0.0%
% of Gross Profit
Operating Expenses $9.253M $14.17M
YoY Change -34.68% 45.07%
Operating Profit -$8.570M -$13.31M
YoY Change -35.62% 71.2%
Interest Expense $233.0K $391.0K
YoY Change -40.41% -43.74%
% of Operating Profit
Other Income/Expense, Net $1.782M -$1.623M
YoY Change -209.8% -288.06%
Pretax Income -$7.020M -$15.33M
YoY Change -54.21% 101.45%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$7.021M -$15.33M
YoY Change -54.19% 101.46%
Net Earnings / Revenue -1027.96% -1794.5%
Basic Earnings Per Share -$0.56 -$0.25
Diluted Earnings Per Share -$0.56 -$0.25
COMMON SHARES
Basic Shares Outstanding 12.46M 60.55M
Diluted Shares Outstanding 12.46M 60.55M

Balance Sheet

Concept 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.50M $44.70M
YoY Change -31.77% -1.76%
Cash & Equivalents $16.80M $20.81M
Short-Term Investments $13.70M $23.90M
Other Short-Term Assets $800.0K $1.300M
YoY Change -38.46% 30.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $31.30M $46.00M
YoY Change -31.95% -1.11%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $53.00K
YoY Change -100.0% 96.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $0.00 $53.00K
YoY Change -100.0% 23.26%
TOTAL ASSETS
Total Short-Term Assets $31.30M $46.00M
Total Long-Term Assets $0.00 $53.00K
Total Assets $31.30M $46.05M
YoY Change -32.03% -1.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.800M $772.0K
YoY Change 133.16% -47.09%
Accrued Expenses $6.100M $9.600M
YoY Change -36.46% 18.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $5.900M $9.900M
YoY Change -40.4% 12.5%
Total Short-Term Liabilities $16.14M $37.31M
YoY Change -56.72% 5.58%
LONG-TERM LIABILITIES
Long-Term Debt $1.900M $1.700M
YoY Change 11.76% -84.96%
Other Long-Term Liabilities $1.200M $3.400M
YoY Change -64.71% -40.35%
Total Long-Term Liabilities $3.100M $5.100M
YoY Change -39.22% -70.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.14M $37.31M
Total Long-Term Liabilities $3.100M $5.100M
Total Liabilities $19.30M $42.40M
YoY Change -54.48% -18.93%
SHAREHOLDERS EQUITY
Retained Earnings -$547.8M -$521.4M
YoY Change 5.07% 10.34%
Common Stock $559.9M $525.0M
YoY Change 6.64% 12.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.06M $3.615M
YoY Change
Total Liabilities & Shareholders Equity $31.32M $46.05M
YoY Change -32.0% -1.08%

Cashflow Statement

Concept 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$7.021M -$15.33M
YoY Change -54.19% 101.46%
Depreciation, Depletion And Amortization $0.00 $10.00K
YoY Change -100.0% 0.0%
Cash From Operating Activities -$9.650M -$12.54M
YoY Change -23.05% 44.3%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$30.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $5.560M $7.860M
YoY Change -29.26% -59.51%
Cash From Investing Activities $5.560M $7.850M
YoY Change -29.17% -59.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 590.0K -1.250M
YoY Change -147.2% -128.34%
NET CHANGE
Cash From Operating Activities -9.650M -12.54M
Cash From Investing Activities 5.560M 7.850M
Cash From Financing Activities 590.0K -1.250M
Net Change In Cash -3.500M -5.940M
YoY Change -41.08% -139.26%
FREE CASH FLOW
Cash From Operating Activities -$9.650M -$12.54M
Capital Expenditures $0.00 -$30.00K
Free Cash Flow -$9.650M -$12.51M
YoY Change -22.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
16144000
CY2015Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1221000
CY2014Q3 us-gaap Revenues
Revenues
854000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1623000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4635000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4405000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3543000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
6238000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4832000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-34166000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
24352000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
31450000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
206000
snss Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
40024000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5385000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5686000
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-547795000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31316000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
8000
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
559847000
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2015Q3 snss License And Other Revenue
LicenseAndOtherRevenue
683000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
12058000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-181000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
276000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2512000
snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-1129000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
94000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-796000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-296000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2319000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-29455000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5259000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6939000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3994000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7226000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
7098000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
6937000
snss Proceeds From Exercise Of Warrants Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfWarrantsStockOptionsAndStockPurchaseRights
489000
snss Proceeds From Exercise Of Warrants Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfWarrantsStockOptionsAndStockPurchaseRights
1833000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
16972000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
39646000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15121000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20807000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1642000
snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
18125000
snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
4726000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
9253000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
14165000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8570000
CY2015Q3 us-gaap Interest Expense
InterestExpense
233000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27962000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1387000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1782000
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Revenues
Revenues
2391000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16073000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14280000
CY2015Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
1893000
us-gaap Operating Expenses
OperatingExpenses
30353000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant Estimates and Judgments </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s consolidated financial statements and accompanying notes thereto. Actual results could differ materially from these estimates. Estimates, assumptions and judgments made by management include those related to the valuation of equity and related instruments, revenue recognition, stock-based compensation and clinical trial accounting. </p></div>
CY2014Q3 snss License And Other Revenue
LicenseAndOtherRevenue
854000
snss License And Other Revenue
LicenseAndOtherRevenue
2391000
CY2014Q3 us-gaap Interest Expense
InterestExpense
391000
us-gaap Interest Expense
InterestExpense
705000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13311000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3569000
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
60549000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
18000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
106000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
300000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-422000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-7021000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-15325000
us-gaap Net Income Loss
NetIncomeLoss
-25098000
CY2015Q3 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
3000
CY2014Q3 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
-2000
us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
5000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7018000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15327000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25093000
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
74776000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19601000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28299000
CY2015Q3 us-gaap Revenues
Revenues
683000
snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-1203000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
59052000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
37947000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71670000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
38201000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2015Q3 snss Investments Denominated In Euros Owned At Fair Value
InvestmentsDenominatedInEurosOwnedAtFairValue
700000
CY2014Q4 snss Investments Denominated In Euros Owned At Fair Value
InvestmentsDenominatedInEurosOwnedAtFairValue
0
CY2015Q3 snss Revenue Participation Right Payment Rate
RevenueParticipationRightPaymentRate
0.0675
snss Revenue Participation Right Payment Term
RevenueParticipationRightPaymentTerm
10 years from the date of first commercial sale
snss Maximum Term Of Revenue Participation Right Payments
MaximumTermOfRevenueParticipationRightPayments
P10Y
us-gaap Stock Issued1
StockIssued1
4486000
snss Transfer Of Fair Value Of Exercised Warrants To Additional Paid In Capital
TransferOfFairValueOfExercisedWarrantsToAdditionalPaidInCapital
496000
us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
100000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1998-02-10
CY2015Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
30500000
snss Securities Policy Maturity Limit Period
SecuritiesPolicyMaturityLimitPeriod
P24M
snss Securities Policy Dollar Weighted Average Maturity Limit Period
SecuritiesPolicyDollarWeightedAverageMaturityLimitPeriod
P12M
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19601000
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28299000
CY2015Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
24608000
CY2015Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2015Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
24606000
CY2015Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
10904000
CY2015Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
2000
CY2015Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
7554000
CY2015Q3 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
13704000
CY2015Q3 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
2000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
30334000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
30327000
CY2014Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9532000
CY2014Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
20802000
CY2014Q4 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
7000
CY2014Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
9532000
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P0Y
CY2014 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P9M18D
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.772
CY2014 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.449
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.000
CY2014 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.002
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000
CY2014 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000
CY2015Q3 snss Warrants Estimated Fair Value Per Warrant Share
WarrantsEstimatedFairValuePerWarrantShare
0.00
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2015Q3 snss Common Stock Fair Value
CommonStockFairValue
0.81
CY2014Q4 snss Common Stock Fair Value
CommonStockFairValue
2.55
CY2015Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.52
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.52
CY2014Q4 snss Warrants Estimated Fair Value Per Warrant Share
WarrantsEstimatedFairValuePerWarrantShare
1.21
CY2015Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2920000
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2920000
CY2015Q2 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
900000
CY2015Q3 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
600000
CY2015Q3 us-gaap Notes Payable
NotesPayable
7754000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1303000
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1635000

Files In Submission

Name View Source Status
0001564590-15-009661-index-headers.html Edgar Link pending
0001564590-15-009661-index.html Edgar Link pending
0001564590-15-009661.txt Edgar Link pending
0001564590-15-009661-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g20151103213717466271.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snss-10q_20150930.htm Edgar Link pending
snss-20150930.xml Edgar Link completed
snss-20150930.xsd Edgar Link pending
snss-20150930_cal.xml Edgar Link unprocessable
snss-20150930_def.xml Edgar Link unprocessable
snss-20150930_lab.xml Edgar Link unprocessable
snss-20150930_pre.xml Edgar Link unprocessable
snss-ex105_11.htm Edgar Link pending
snss-ex311_6.htm Edgar Link pending
snss-ex312_7.htm Edgar Link pending
snss-ex321_8.htm Edgar Link pending